Udall J A
Postgrad Med. 1976 Aug;60(2):65-9. doi: 10.1080/00325481.1976.11708376.
Short-term anticoagulant therapy given after an acute myocardial infarction is directed toward preventing thromboembolism and is fairly safe. Long-term anticoagulant therapy prevents coronary thrombosis in selected patients with coronary heart disease (CHD), but carries an appreciable risk of hemorrhage. A decision for or against short-term therapy should be based on an assessment of the immediate risk of thromboembolism. Similarly, the risk of coronary thrombosis should be the major determinant in a decision for or against long-term anticoagulation. The most important information emerging from the clinical trials of long-term anticoagulant therapy in CHD concerns the significant benefit observed among patients with advanced disease.
急性心肌梗死后给予的短期抗凝治疗旨在预防血栓栓塞，且相当安全。长期抗凝治疗可预防部分冠心病（CHD）患者的冠状动脉血栓形成，但有明显的出血风险。决定是否进行短期治疗应基于对血栓栓塞近期风险的评估。同样，冠状动脉血栓形成的风险应是决定是否进行长期抗凝的主要决定因素。冠心病长期抗凝治疗临床试验中出现的最重要信息是，在病情严重的患者中观察到了显著益处。
